Investing Gets a Boost as Rubicon Research Announces ₹1377.5 Crore IPO

Rubicon Research, a leading pharmaceutical formulations firm, is launching a ₹1377.5 crore IPO. The issue comprises a new equity issue of ₹500 crore and an offer for sale of ₹877.5 crore by promoter General Atlantic Singapore. The IPO opens on October 9 and closes on October 13, with a tentative listing scheduled for October 16 on NSE and BSE. Funds will be used for debt repayment, inorganic growth, and strategic initiatives. The company specializes in R&D and innovative drug-device combinations, with a strong USFDA portfolio.

 

Sources: The Hindu Business Line, Moneycontrol, IPOWatch, Upstox, Economic Times